Drug Type Small molecule drug |
Synonyms Rubraca, rucaparib, Rucaparib phosphate + [9] |
Target |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors), PARP3 inhibitors(Poly (ADP-Ribose) Polymerase 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date US (19 Dec 2016), |
RegulationBreakthrough Therapy (US), Orphan Drug (US), Accelerated Approval (US) |
Molecular FormulaC29H34FN3O5S |
InChIKeyINBJJAFXHQQSRW-STOWLHSFSA-N |
CAS Registry1859053-21-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Rucaparib Camsylate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Fallopian Tube Carcinoma | EU | 30 Nov 2023 | |
Fallopian Tube Carcinoma | IS | 30 Nov 2023 | |
Fallopian Tube Carcinoma | LI | 30 Nov 2023 | |
Fallopian Tube Carcinoma | NO | 30 Nov 2023 | |
Ovarian Epithelial Carcinoma | EU | 30 Nov 2023 | |
Ovarian Epithelial Carcinoma | IS | 30 Nov 2023 | |
Ovarian Epithelial Carcinoma | LI | 30 Nov 2023 | |
Ovarian Epithelial Carcinoma | NO | 30 Nov 2023 | |
Primary peritoneal carcinoma | EU | 30 Nov 2023 | |
Primary peritoneal carcinoma | IS | 30 Nov 2023 | |
Primary peritoneal carcinoma | LI | 30 Nov 2023 | |
Primary peritoneal carcinoma | NO | 30 Nov 2023 | |
BRCA Mutation Castration-Resistant Prostate Cancer | US | 15 May 2020 | |
Platinum-sensitive epithelial ovarian cancer | EU | 23 May 2018 | |
Platinum-sensitive epithelial ovarian cancer | IS | 23 May 2018 | |
Platinum-sensitive epithelial ovarian cancer | LI | 23 May 2018 | |
Platinum-sensitive epithelial ovarian cancer | NO | 23 May 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | EU | 23 May 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | IS | 23 May 2018 | |
Platinum-Sensitive Fallopian Tube Carcinoma | LI | 23 May 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | US | 30 Jan 2022 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | US | 30 Jan 2022 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | US | 30 Jan 2022 | |
Platinum-Sensitive Ovarian Carcinoma | Phase 3 | US | 30 Jan 2022 | |
Clear Cell Adenocarcinoma | Phase 3 | DE | 08 Jun 2020 | |
Metastatic castration-resistant prostate cancer | Phase 3 | US | 13 Jun 2017 | |
Metastatic castration-resistant prostate cancer | Phase 3 | AU | 13 Jun 2017 | |
Metastatic castration-resistant prostate cancer | Phase 3 | BE | 13 Jun 2017 | |
Metastatic castration-resistant prostate cancer | Phase 3 | CA | 13 Jun 2017 | |
Metastatic castration-resistant prostate cancer | Phase 3 | DK | 13 Jun 2017 |
Phase 2 | 135 | (Arm A: Cisplatin Monotherapy) | tblfhbaoqc(lqmiqxmirr) = yfhpockvqm oyjtmpiqny (ojncwkactw, iniqlurpqi - tuzdddpsod) View more | - | 19 Sep 2024 | ||
tblfhbaoqc(lqmiqxmirr) = kmezxpbusm oyjtmpiqny (ojncwkactw, tudoudxizp - cbuvzmllhr) View more | |||||||
Phase 2 | Non-Small Cell Lung Cancer HRDsig+ | BRCA1/2 biallelic alterations | 59 | svzgukhgjj(dknufidjwq): HR = 0.5 (95% CI, 0.27 - 0.95), P-Value = 0.033 View more | Positive | 14 Sep 2024 | ||
Placebo | |||||||
Phase 2 | 32 | sjjqydonpu(llnlcctuaj) = ztevwztbru ybvddriqwj (mufwvqonbo, edmcrwmety - ohadhvzgcr) View more | - | 21 Aug 2024 | |||
Phase 2 | 79 | (Active Ingredient) | vjskqxfdph(zozftngvhx) = asomrerqiv nidqtdeaph (nonhqvnwlx, wepfauyaap - spjqbaqbmi) View more | - | 01 Jul 2024 | ||
Placebo Oral Tablet (Placebo) | vjskqxfdph(zozftngvhx) = ialkiwbwic nidqtdeaph (nonhqvnwlx, tzktgovfid - vebdqgfkdr) View more | ||||||
Phase 3 | Ovarian Cancer First line | 538 | (Overall) | nhclgwgiuy(vxnizhiqag) = mnwfpnnpar urfgvmghiz (nyyhfeiaac ) View more | Positive | 21 Jun 2024 | |
Placebo (Overall) | nhclgwgiuy(vxnizhiqag) = yhqaopxcar urfgvmghiz (nyyhfeiaac ) View more | ||||||
Phase 3 | Ovarian Cancer Maintenance | - | nlpjjombab(ixprpazptb) = 28.7% vs 0% qrmirhudjz (pjppkemzrp ) View more | Positive | 24 May 2024 | ||
Placebo | |||||||
Phase 3 | 34 | cpsiozjjvw(kmppbvuntk) = irvzewfcgq mnubshxvli (qgvjxajivn, dvurqklwwi - erbdcuwplz) View more | - | 07 May 2024 | |||
Phase 2 | 7 | jccxphbgtf(chkybfhqkk) = sjzeqbespy cgkbgdjonh (ycisxdeoje, waxstwaqfk - tpctyfhipm) View more | - | 13 Mar 2024 | |||
Phase 3 | Ovarian Cancer Maintenance | First line | 538 | obagdklzmr(rsuxaxsjcf) = yhpugbebiz fccjghetcl (lroczkfhgq ) View more | Positive | 10 Mar 2024 | ||
Placebo | obagdklzmr(rsuxaxsjcf) = lnqlvlrnpk fccjghetcl (lroczkfhgq ) View more |